U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. About Science & Research at FDA
  4. FDA Grand Rounds
  1. About Science & Research at FDA
FDA Grand Rounds Image

The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.

Laboratory and Clinical Studies to Investigate Whether Ranitidine Converts to a Probable Carcinogen in Humans

Thursday, October 14, 2021
12:00 p.m. - 1:00 p.m. EST

About the Speakers

David Keire, PhD
Director of Testing and Research
Office of Testing and Research
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research (CDER)

Dr. David Keire received a Ph.D. in Analytical Chemistry at the University of California, Riverside in 1990 with a focus on nuclear magnetic resonance (NMR) spectroscopy. Dr. Keire joined the Center for Drug Evaluation and Research’s Office of Testing and Research (OTR) in 2008 and provided expertise in characterizing complex drugs such as heparin. He is now the OTR Office Director and for the past three years he has participated in the Office of Pharmaceutical Quality (OPQ) and the CDER Nitrosamine Task Forces and international nitrosamine working groups.

Jeffry Florian, PhD
Associate Director
Division of Applied Regulatory Science
Office of Clinical Pharmacology, Office of Translational Sciences
Center for Drug Evaluation and Research (CDER)

Dr. Jeffry Florian is the Associate Director in the Division of Applied Regulatory Science (DARS) where his primary responsibilities have included clinical trial design, drug-disease modeling, and biomarker identification for biosimilar development. Jeffry is prominently involved in expanding the clinical study research capabilities within the Division of Applied Regulatory Science (DARS). His work spans topics such as sunscreen absorption, biomarker identification for biosimilar development, opioid safety with concomitant medications, opioid antagonist drug development and use, and urinary excretion of ranitidine metabolites.

About the Presentation

Researchers at the Center for Drug Evaluation and Research (CDER) conducted and published clinical and nonclinical studies in response to concerns whether ranitidine converts to the probable human carcinogen N-nitrosodimethylamine (NDMA) in humans. This research found no evidence of elevated NDMA content in urine or blood when participants consumed ranitidine and showed that ranitidine does not convert to NDMA in vitro studies under physiologic gastric nitrite concentrations.

Past Grand Rounds







Resources For You

Sub-Topic Paragraphs

Subscribe to FDA Grand Rounds email updates

The latest information on the FDA Grand Rounds

Back to Top